Manufacturers with CMS Agreements As of 5/15/2020 Labeler Code Labeler Name Program End Date 00002 ELI LILLY and COMPANY 00003 E.R
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Corporate Governance Report 2014
CORPORATE GOVERNANCE REPORT Sobi’s Corporate Governance Swedish Orphan Biovitrum AB (publ) “Sobi” is a Swedish adopts the annual report and interim reports, and pro- neration programmes. This includes an overview, and pro- public limited liability company with its registered office poses dividends, if any, to the AGM. posals for remuneration to senior executives and for in Stockholm, Sweden. Sobi is listed on Nasdaq Stock- The Board’s work is based on its working procedures, long-term incentive programmes, pension plans and other holm. In addition to the rules stipulated by law or other CEO instructions and the principles for the division of duties issues relating to remuneration to the company’s employees. statutes, Sobi applies the Swedish Corporate Governance between the CEO, the Chairman of the Board, Board mem- Code complete. This report pertains to the 2014 financial bers and various committees established by the Board. The 6. Scientific Committee year and is a part of Sobi’s Directors’ Report and has been Board’s working procedures and instructions for the CEO The Scientific Committee’s tasks include advising on scien- reviewed by the company’s auditors. are revised and updated once a year. The Chairman of the tific matters, evaluating the Company’s research strategies, Board leads the Board’s work, monitors the company’s per- and monitoring and reporting to the Board on scientific 1. Annual General Meeting formance, ensures that important issues are addressed as trends and new fields of research. Sobi’s highest decision-making body is the Annual General needed and that all important decisions are preceded by Meeting (AGM) at which all shareholders have the right to active and constructive discussion. -
Numeric Listing of Manufacturers That Have Signed Rebate Agreements
Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements January 1, 2020 NEWLABELER NAME START END SC NEW LABELER NAME START END SC 00002 ELI LILLY AND COMPANY 1/1/1991 Y 00172 IVAX PHARMACEUTICALS, INC. 1/1/1991 Y 00003 E.R. SQUIBB & SONS, LLC. 1/1/1991 Y 00173 GLAXOSMITHKLINE 1/1/1991 00004 HOFFMANN-LA ROCHE 1/1/1991 00178 MISSION PHARMACAL COMPANY 1/1/1991 00006 MERCK & CO., INC. 1/1/1991 Y 00182 GOLDLINE LABORATORIES, INC. 1/1/1991 00007 GLAXOSMITHKLINE 1/1/1991 00185 EON LABS, INC. 1/1/1991 Y 00008 WYETH LABORATORIES 1/1/1991 Y 00186 ASTRAZENECA PHARMACEUTICAL 1/1/1991 Y 00009 PHARMACIA AND UPJOHN COMPA 1/1/1991 Y 00187 BAUSCH HEALTH US, LLC. 1/1/1991 Y 00013 PHARMACIA AND UPJOHN COMPA 1/1/1991 Y 00206 WYETH PHARMACEUTICALS LLC 1/1/1991 Y 00015 MEAD JOHNSON AND COMPANY 1/1/1991 Y 00224 KONSYL PHARMACEUTICALS, INC. 1/1/1992 00023 ALLERGAN INC 1/1/1991 00225 B. F. ASCHER AND COMPANY, INC. 1/1/1991 00024 SANOFI-AVENTIS, US LLC 1/1/1991 Y 00228 ACTAVIS ELIZABETH LLC 1/1/1991 Y 00025 GD. SEARLE LLC DIVISION OF PFIZ 1/1/1991 Y 00245 UPSHER-SMITH LABORATORIES, I 1/1/1991 Y 00026 BAYER HEALTHCARE LLC 1/1/1991 Y 00254 PAR PHARMACEUTTICAL INC. 9/28/2018 00029 GLAXOSMITHKLINE 1/1/1991 00258 FOREST LABORATORIES INC 1/1/1991 00032 ABBVIE INC. 1/1/1991 Y 00259 MERZ PHARMACEUTICALS 1/1/1991 00037 MEDA PHARMACEUTICALS, INC. -
Obesity, Diabetes, & Diet
Obesity, Diabetes, & Diet COMBINING EVIDENCE FOR ALL THREE INTO IMPROVED PATIENT CARE Case Study Louis J. Aronne, MD, FACP Weill Cornell Medical College Columbia University College of Physicians and Surgeons Louis J. Aronne, MD, FACP Disclosures !! Research/Grants: Amylin Pharmaceuticals, Inc.; Arena Pharmaceuticals, Inc.; F. Hoffmann-La Roche, Ltd.; Metabolous Pharmaceuticals, Inc.; Norvo Nordisk; Orexigen Therapeutics, Inc.; Pfizer Inc.; TransTech Pharma, Inc. !! Speakers Bureau: None !! Consultant: Allergan, Inc.; Amylin Pharmaceuticals, Inc.; GI Dynamics, Inc.; GlaxoSmithKline Consumer Healthcare, LP; Johnson & Johnson Pharmaceutical Research & Development, LLC; NeuroSearch, Inc.; Novo Nordisk; Orexigen Therapeutics, Inc.; Roche Laboratories, Inc.; VIVUS, Inc.; Wyeth Pharmaceuticals, Inc. !! Stockholder: Cardiometabolic Support Network, LLC !! Other Financial Interest: None !! Advisory Board: Allergan, Inc.; Amylin Pharmaceuticals, Inc.; GI Dynamics, Inc.; GlaxoSmithKline Consumer Healthcare, LP; Johnson & Johnson Pharmaceutical Research & Development, LLC; NeuroSearch, Inc.; Novo Nordisk; Orexigen Therapeutics, Inc.; Roche Laboratories, Inc.; VIVUS, Inc.; Wyeth Pharmaceuticals, Inc. Father A.V. 04May09: 378 lbs, 5’ 11”, BMI = 53 !! Dx w/ DMII in 2004 !! Long history of obesity !! Can’t control his eating, binges !! HbA1c = 8.4% !! FPG = 166 !! TG = 241 !! UA Microalbumin = 973 !! “Can’t tolerate metformin” !! Considering RYGB, but afraid to have surgery DMII = diabetes mellitus type II; Hb = hemoglobin; FPG = fasting plasma glucose; -
In Re Incretin-Based Therapies Products Liability Litigation Transfer Order
Case MDL No. 2452 Document 71 Filed 08/26/13 Page 1 of 4 UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION IN RE: INCRETIN MIMETICS PRODUCTS LIABILITY LITIGATION MDL No. 2452 TRANSFER ORDER Before the Panel: Pursuant to 28 U.S.C. § 1407, plaintiffs in two Southern District of California actions move to centralize this litigation, which involves four anti-diabetic medications that plaintiffs contend cause pancreatic cancer, in the Southern District of California. This litigation currently consists of 53 actions pending in seven districts, as listed on Schedule A.1 All responding parties support centralization. Plaintiffs in fifteen Southern District of California actions and a District of Arizona action support plaintiffs’ motion in its entirety. Defendants2 support centralization in the Southern District of California or, alternatively, the District of Colorado or the Western District of Oklahoma. On the basis of the papers filed and hearing session held, we find that these actions involve common questions of fact, and that centralization of all actions in the Southern District of California will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. Plaintiffs in all actions allege that the use of one or more of four anti-diabetic incretin- based medications – Janumet (sitagliptin combined with metformin), Januvia (sitagliptin), Byetta (exenatide) and Victoza (liraglutide) – caused them or their decedent to develop pancreatic cancer. Centralization will eliminate duplicative discovery; prevent inconsistent pretrial rulings (particularly on such matters as Daubert rulings); and conserve the resources of the parties, their counsel, and the judiciary. We are “typically hesitant to centralize litigation against multiple, competing defendants which marketed, manufactured and sold similar products.” In re Yellow Brass Plumbing Component Prods. -
References Used in Algorithms for the Treatment of Persons with Crohn’S Disease
REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH CROHN’S DISEASE 1. AA Pharma Inc: Winpred (prednisone). In: CA Product Monograph. Vaughan, ON; 2018. 2. AbbVie Corporation: Humira (adalimumab). In: CA Product Monograph. St Laurent, QC; 2019. 3. AbbVie Inc: Humira (adalimumab). In: US Product Monograph. North Chicago, IL; 2020. 4. Amgen Canada Inc: Avsola (infliximab). In: CA Product Monograph. Mississauga, ON; 2020. 5. Amgen Inc: Amjevita (adalimumab-atto). In: US Product Monograph. Thousand Oaks, CA; 2019. 6. Amgen Inc: Avsola (infliximab-axxq). In: US Product Monograph. Thousand Oaks, CA; 2019. 7. Antares Pharma Inc: Methotrexate. In: FDA Product Monograph. Ewing, NJ; 2019. 8. Apotex Inc: Methotrexate. In: CA Product Monograph. Toronto, ON; 2019. 9. Asada A, Nishida A, Shioya M, Imaeda H, Inatomi O, Bamba S, Kito K, Sugimoto M, Andoh A: NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease. Journal of gastroenterology 2016, 51(1):22-29. 10. Aspen Pharmacare Canada Inc: Imuran (azathioprine). In: CA Product Monograph. Oakville, ON; 2019. 11. Biogen Canada Inc: Tysabri (natalizumab). In: CA Product Monograph. Mississauga, ON; 2017. 12. Biogen Idec Inc: Tysabri (natalizumab). In: US Product Monograph. Cambridge, MA; 2019. 13. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ et al: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clinical pharmacology and therapeutics 2015, 98(1):19-24. 14. Boehringer Ingelheim Pharmaceuticals Inc: Cyltezo (adalimumab-adbm). In: US Product Monograph. Ridgefield, CT; 2019. -
Curriculum Vitae
David C. Klonoff MD, FACP, FRCP (Edin), Fellow AIMBE Page 1 CURRICULUM VITAE DAVID CHARLES KLONOFF, M.D., FACP, FRCP (Edin), FELLOW AIMBE Medical Director, Diabetes Research Institute, Mills-Peninsula Medical Center 100 South San Mateo Drive, Room 5147, San Mateo, California 94401 Phone 650-696-4260 / Fax 650-696-4269 [email protected] SUMMARY David C. Klonoff, M.D. is an endocrinologist specializing in the development and use of diabetes technology. He is Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center in San Mateo, California and a Clinical Professor of Medicine at UCSF. Dr. Klonoff received the American Diabetes Association’s 2019 Outstanding Physician Clinician Award. He received an FDA Director’s Special Citation Award in 2010 for outstanding contributions related to diabetes technology. In 2012 Dr. Klonoff was elected as a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and cited as among the top 2% of the world’s bioengineers for his engineering work in diabetes technology. He received the 2012 Gold Medal Oration and Distinguished Scientist Award from the Dr. Mohan’s Diabetes Specialities Centre and Madras Diabetes Research Foundation of Chennai, India. Dr. Klonoff was invited to speak to the US Congressional Diabetes Caucus in 2017, participate in the White House Health and Cybersecurity Roundtable in 2015, and speak at the European Parliament in 2010. He is the Founding Editor- in-Chief of Journal of Diabetes Science and Technology. He has authored over 270 publications in PubMed journals including four of the first ten articles on diabetes device cybersecurity. -
DIE PHARMAZEUTISCHE INDUSTRIE in DEUTSCHLAND in Milliarden Euro Ein Branchenportrait
Die pharmazeutische Industrie auf einen Blick in Milliarden Euro Umsatz 2016 2017 48,2 49,0 in Milliarden Euro in Prozent des Umsatzes (Exportquote) Auslandsumsatz 2016 2017 2016 2017 32,0 32,5 66,5 66,2 in Milliarden Euro Produktion 29,2 30,6 2016 2017 Beschäftigte 115.663 117.013 2016 2017 in Milliarden Euro Investitionen in Sachanlagen 2015 1,6 2016 2,1 Investitionen in Prozent des Umsatzes Investitionsquote 2015 3,4 2016 4,6 DIE PHARMAZEUTISCHE INDUSTRIE IN DEUTSCHLAND in Milliarden Euro Ein Branchenportrait F&E-Aufwendungen 6,1 6,2 2015 2016 in Vollzeitäquivalenten vfa Institut der deutschen Wirtschaft F&E-Beschäftigte 18.357 19.429 Verband der forschenden Pharma-Unternehmen Forschungsstelle Pharmastandort Deutschland Hausvogteiplatz 13 Konrad-Adenauer-Ufer 21 2015 2016 10117 Berlin 50668 Köln Telefon: 030 20604-0 Telefon: 0221 4981-813 Quellen: Statistisches Bundesamt, Stifterverband für die Deutsche Wissenschaft www.vfa.de www.pharmastandort.de 4., überarbeitete Auflage Inhalt Die Standorte derDie vfa-Mitglieder Standorte der vfa-Mitglieder und ihrer Tochterunternehmen vfa-Mitgliedsunternehmen und ihrer Tochterunternehmen Vorwort Chancen der Digitalisierung für die Patientenversorgung nutzen 1 Bad Oldesloe GSK D Allergopharma (Tochter von Merck) Wedel Forschung und Innovation in der Pharmaindustrie Reinbek S F K M D B H Digitalisierung als Treiber medizinischer Innovationen 2 Hamburg Takeda D H 1 Bayer F K M D H Berlin-Chemie S K M H Be the Partner S Wirtschaftsfaktor Pharma S K M D AstraZeneca JPT Peptide Technologies S K M Lundbeck -
11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC. -
Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA SAN DIEGO and INDIANAPOLIS, Aug 26, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) in a conference call today provided context and additional information regarding the August 18, 2008 U.S. Food and Drug Administration (FDA) update to a prior alert for BYETTA® (exenatide) injection referencing pancreatitis. The companies were aware of the pancreatitis cases referenced in the alert, as well as others, and previously reported these cases to the FDA. The complete conference call replay will be available through Amylin's and Lilly's corporate websites after the call. Since 2006, the U.S. prescribing information for BYETTA has included information about pancreatitis. A recent study has also shown that patients with type 2 diabetes were at nearly three times the risk of developing pancreatitis than those without diabetes.(1) While a definite causal relationship between BYETTA and pancreatitis has not been proved, to better understand the suspected relationship, Amylin and Lilly continue to pursue a comprehensive drug safety program that includes extensive internal and external review of individual cases, and clinical and epidemiologic studies. "At Amylin and Lilly, patient safety is our foremost concern. We are committed to continuing to work closely with the FDA to ensure that physicians and patients are provided with accurate information about any potential risks associated with the use of our products," said Orville G. Kolterman, Senior Vice President, Research and Development at Amylin. "It is important to understand that pancreatitis, an inflammatory condition of the pancreas, is a rare event. -
Long Term Care Pharmacy
2201812 Long Term Care Pharmacy Long-Term Care Pharmacy of charge as value-added services. They include: Our mission is to provide our long-term care pharmacy › Access to our staff of eight in-house clinical experts. members with the tools they need to maximize savings › CE credits through a monthly teleconference program, while enhancing the quality of care they provide. In 1993, in-person programming, and written education Innovatix began as a pharmacy-focused GPO, and over programs. the years has become the industry leader with over 15,000 › Care Solutions manuals that serve as management unique NDCs and a number of pharmacy support products guides for specific diseases and conditions. and services. As a wholly-owned subsidiary of Premier, › Contract Advantage tools that help members save by Innovatix also offers members access to one of the most providing contracted alternatives to higher-priced non- robust, competitive equipment, supply, and service contracted drugs. portfolios available. › Updated clinical news and resources. GPO Support Services Multi-Tiered Customer Support At Innovatix, we realize that securing best-in-class pricing Innovatix members receive ongoing support from a is only half of the equation. That’s why we’ve developed team of experienced professionals who are committed a suite of tools and services designed to ensure our to delivering exceptional value and complete member members receive discounted pricing and have sufficient satisfaction. Our customer care teams work with each data to make informed purchasing decisions. Our tools member individually, analyzing data to identify purchasing and services include: needs and goals. Our objective is to secure the greatest › Electronic contract attachment technology designed to value for each of our members. -
Pharmaceutical Company Contact Information (PDF)
Pharmaceutical Company Contact Information - Rebate Filing - as of June 2018 Labeler Name Invoice Contact Phone Extension 00002 LILLY USA, LLC LISA NORTON (317) 276-2000 00003 ER SQUIBB AND SONS INC. LYNN LEWIS (609) 897-4731 00004 GENENTECH CONTRACT ADMINISTRATION (650) 866-2666 00005 LEDERLE LABORATORIES DAN MAGUIRE (484) 563-5097 00006 MERCK & CO., INC. DOUG BICKFORD (215) 652-0671 00007 SMITHKLINE BEECHAM DAVID BUCKLEY (215) 751-5690 00008 WYETH LABORATORIES JENNIFER WOOTEN (901) 215-1883 00009 PHARMACIA AND UPJOHN COMPANY/PFIZER JENNIFER WOOTEN (901) 215-1883 00013 PHARMACIA AND UPJOHN COMPANY NICHOLAS CHRISTODOULOU (336) 291-1053 00014 G. D. SEARLE & CO. CINDY MCDONALD (847) 581-5726 00015 MEAD JOHNSON AND COMPANY LYNN LEWIS (609) 897-4731 00016 PHARMACIA INC. BARBARA WINGET (908) 901-7254 00023 ALLERGAN INC SHOBHANA MINAWALA (714) 246-6205 00024 SANOFI WINTHROP PHARMACEUTICALS LAURIE DUNLAP, ADMIN., GOVT. OPERATIONS (212) 551-4198 00025 PHARMACIA CORPORATION NICHOLAS CHRISTODOULOU (336) 291-1053 00026 BAYER CORPORATION PHARMACEUTICAL DIV. LINDA WOLCHESKI (203) 812-6372 00028 NOVARTIS PHARMACEUTICALS (862) 778-8094 00029 SMITHKLINE BEECHAM DAVID BUCKLEY (215) 751-5690 00031 A. H. ROBINS COMPANY DAN MAGUIRE (610) 902-3222 00032 SOLVAY PHARMACEUTICALS STACEY LENOX (847) 937-3979 00033 SYNTEX LABORATORIES, INC. JANICE BRENNAN (973) 562-3494 00034 THE PURDUE FREDERICK COMPANY JUNE STOWE (203) 899-8035 00037 CARTER-WALLACE, INC. JAY R BRENNAN (609) 655-6163 00038 ASTRAZENECA LP DAVID WRIGHT (302) 886-2268 7820 00039 AVENTIS PHARMACEUTICALS (908) 981-7461 00043 NOVARTIS CONSUMER HEALTH, INC. EDWARD D. COLLINS (973) 781-6191 00044 KNOLL LABORATORIES DEBRA DEYOUNG (847) 937-4372 00045 MCNEIL PHARMACEUTICAL (908) 218-6777 00046 AYERST LABORATORIES (901) 215-1473 00047 WARNER CHILCOTT LABORATORIES LISA KAROLCHYK (973) 442-3262 00048 KNOLL PHARMACEUTICAL COMPANY DEBRA DEYOUNG (847) 937-4372 00049 ROERIG NICHOLAS CHRISTODOULOU (336) 291-1053 00051 UNIMED PHARMACEUTICALS, INC STACY LENOX (847) 937-3979 00052 ORGANON, USA, INC. -
05/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 04:25:50 Report Id 2794D052 Page: 01
MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 05/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 04:25:50 REPORT ID 2794D052 PAGE: 01 ALPHA COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 07/01/2016 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 68782 (OSI) EYETECH 55513 AMGEN USA 00074 ABBOTT LABORATORIES 58406 AMGEN/IMMUNEX 68817 ABRAXIS BIOSCIENCE, LLC 53746 AMNEAL PHARMACEUTICALS 16729 ACCORD HEALTHCARE INCORPORATED 65162 AMNEAL PHARMACEUTICALS LLC 42192 ACELLA PHARMACEUTICALS, LLC 69238 AMNEAL PHARMACEUTICALS, LLC 10144 ACORDA THERAPEUTICS, INC. 53150 AMNEAL-AGILA, LLC 00472 ACTAVIS 00548 AMPHASTAR PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 69918 AMRING PHARMACEUTICALS, INC. 45963 ACTAVIS INC. 66780 AMYLIN PHARMACEUTICALS, INC. 46987 ACTAVIS KADIAN LLC 55724 ANACOR PHARMACEUTICALS 49687 ACTAVIS KADIAN LLC 10370 ANCHEN PHARMACEUTICALS, INC. 14550 ACTAVIS PHARMA MFGING PRIVATE LIMITED 43595 ANGELINI PHARMA, INC. 61874 ACTAVIS PHARMA, INC. 62559 ANIP ACQUISITION COMPANY 67767 ACTAVIS SOUTH ATLANTIC 54436 ANTARES PHARMA, INC. 66215 ACTELION PHARMACEUTICALS U.S., INC. 52609 APO-PHARMA USA, INC. 52244 ACTIENT PHARMACEUTICALS 60505 APOTEX CORP. 75989 ACTON PHARMACEUTICALS 63323 APP PHARMACEUTICALS, LLC. 69547 ADAPT PHARMA INC. 43485 APRECIA PHARMACEUTICALS COMPANY 76431 AEGERION PHARMACEUTICALS, INC. 42865 APTALIS PHARMA US, INC 50102 AFAXYS, INC. 58914 APTALIS PHARMA US, INC. 10572 AFFORDABLE PHARMACEUTICALS, LLC 13310 AR SCIENTIFIC, INC. 27241 AJANTA PHARMA LIMITED 08221 ARBOR PHARM IRELAND LIMITED 17478 AKORN INC 60631 ARBOR PHARMACEUTICALS IRELAND LIMITED 24090 AKRIMAX PHARMACEUTICALS LLC 24338 ARBOR PHARMACEUTICALS, INC. 68220 ALAVEN PHARMACEUTICAL, LLC 59923 AREVA PHARMACEUTICALS 00065 ALCON LABORATORIES, INC. 76189 ARIAD PHARMACEUTICALS, INC. 00998 ALCON LABORATORIES, INC. 24486 ARISTOS PHARMACEUTICALS, INC.